Claire L Simons1, Oliver Rivero-Arias, Ly-Mee Yu, Judit Simon. 1. Health Economics Research Centre (HERC), Nuffield Department of Population Health, University of Oxford, Old Road Campus, Headington, Oxford, OX3 7LF, UK.
Abstract
PURPOSE: Missing data are a well-known and widely documented problem in cost-effectiveness analyses alongside clinical trials using individual patient-level data. Current methodological research recommends multiple imputation (MI) to deal with missing health outcome data, but there is little guidance on whether MI for multi-attribute questionnaires, such as the EQ-5D-3L, should be carried out at domain or at summary score level. In this paper, we evaluated the impact of imputing individual domains versus imputing index values to deal with missing EQ-5D-3L data using a simulation study and developed recommendations for future practice. METHODS: We simulated missing data in a patient-level dataset with complete EQ-5D-3L data at one point in time from a large multinational clinical trial (n = 1,814). Different proportions of missing data were generated using a missing at random (MAR) mechanism and three different scenarios were studied. The performance of using each method was evaluated using root mean squared error and mean absolute error of the actual versus predicted EQ-5D-3L indices. RESULTS: In large sample sizes (n > 500) and a missing data pattern that follows mainly unit non-response, imputing domains or the index produced similar results. However, domain imputation became more accurate than index imputation with pattern of missingness following an item non-response. For smaller sample sizes (n < 100), index imputation was more accurate. When MI models were misspecified, both domain and index imputations were inaccurate for any proportion of missing data. CONCLUSIONS: The decision between imputing the domains or the EQ-5D-3L index scores depends on the observed missing data pattern and the sample size available for analysis. Analysts conducting this type of exercises should also evaluate the sensitivity of the analysis to the MAR assumption and whether the imputation model is correctly specified.
PURPOSE: Missing data are a well-known and widely documented problem in cost-effectiveness analyses alongside clinical trials using individual patient-level data. Current methodological research recommends multiple imputation (MI) to deal with missing health outcome data, but there is little guidance on whether MI for multi-attribute questionnaires, such as the EQ-5D-3L, should be carried out at domain or at summary score level. In this paper, we evaluated the impact of imputing individual domains versus imputing index values to deal with missing EQ-5D-3L data using a simulation study and developed recommendations for future practice. METHODS: We simulated missing data in a patient-level dataset with complete EQ-5D-3L data at one point in time from a large multinational clinical trial (n = 1,814). Different proportions of missing data were generated using a missing at random (MAR) mechanism and three different scenarios were studied. The performance of using each method was evaluated using root mean squared error and mean absolute error of the actual versus predicted EQ-5D-3L indices. RESULTS: In large sample sizes (n > 500) and a missing data pattern that follows mainly unit non-response, imputing domains or the index produced similar results. However, domain imputation became more accurate than index imputation with pattern of missingness following an item non-response. For smaller sample sizes (n < 100), index imputation was more accurate. When MI models were misspecified, both domain and index imputations were inaccurate for any proportion of missing data. CONCLUSIONS: The decision between imputing the domains or the EQ-5D-3L index scores depends on the observed missing data pattern and the sample size available for analysis. Analysts conducting this type of exercises should also evaluate the sensitivity of the analysis to the MAR assumption and whether the imputation model is correctly specified.
Authors: T Kendrick; L Simons; L Mynors-Wallis; A Gray; J Lathlean; R Pickering; S Harris; O Rivero-Arias; K Gerard; C Thompson Journal: Br J Psychiatry Date: 2006-07 Impact factor: 9.319
Authors: Hans-Helmut König; Anja Born; Oliver Günther; Herbert Matschinger; Sven Heinrich; Steffi G Riedel-Heller; Matthias C Angermeyer; Christiane Roick Journal: Health Qual Life Outcomes Date: 2010-05-05 Impact factor: 3.186
Authors: M F Janssen; A Simon Pickard; Dominik Golicki; Claire Gudex; Maciej Niewada; Luciana Scalone; Paul Swinburn; Jan Busschbach Journal: Qual Life Res Date: 2012-11-25 Impact factor: 4.147
Authors: Susan Gachau; Edmund Njeru Njagi; Nelson Owuor; Paul Mwaniki; Matteo Quartagno; Rachel Sarguta; Mike English; Philip Ayieko Journal: J Appl Stat Date: 2021-03-17 Impact factor: 1.416
Authors: Ângela Jornada Ben; Johanna M van Dongen; Mohamed El Alili; Martijn W Heymans; Jos W R Twisk; Janet L MacNeil-Vroomen; Maartje de Wit; Susan E M van Dijk; Teddy Oosterhuis; Judith E Bosmans Journal: Eur J Health Econ Date: 2022-09-26
Authors: Ines Rombach; Oliver Rivero-Arias; Alastair M Gray; Crispin Jenkinson; Órlaith Burke Journal: Qual Life Res Date: 2016-01-28 Impact factor: 4.147
Authors: Daniel S March; Adam W Hurt; Charlotte E Grantham; Darren R Churchward; Hannah M L Young; Patrick J Highton; Maurice Dungey; Nicolette C Bishop; Alice C Smith; Matthew P M Graham-Brown; Nicola J Cooper; James O Burton Journal: Kidney Int Rep Date: 2021-04-08